Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Omeros Corp (OMER)

Omeros Corp (OMER)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 969,786
  • Shares Outstanding, K 71,996
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,350 K
  • EBIT $ -123 M
  • EBITDA $ -123 M
  • 60-Month Beta 2.53
  • Price/Sales N/A
  • Price/Cash Flow 6.70
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 87.81% (+10.96%)
  • Historical Volatility 69.61%
  • IV Percentile 27%
  • IV Rank 10.69%
  • IV High 355.15% on 05/16/25
  • IV Low 55.81% on 02/13/26
  • Expected Move (DTE 24) 1.96 (14.51%)
  • Put/Call Vol Ratio 0.48
  • Today's Volume 3,837
  • Volume Avg (30-Day) 2,651
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 41,836
  • Open Int (30-Day) 45,908
  • Expected Range 11.52 to 15.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.40
  • Number of Estimates 1
  • High Estimate $-0.40
  • Low Estimate $-0.40
  • Prior Year $-0.65
  • Growth Rate Est. (year over year) +38.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.77 +37.87%
on 03/30/26
13.94 -3.37%
on 04/20/26
+2.47 (+22.45%)
since 03/20/26
3-Month
9.77 +37.87%
on 03/30/26
13.94 -3.37%
on 04/20/26
+1.21 (+9.87%)
since 01/20/26
52-Week
2.95 +356.61%
on 07/01/25
17.65 -23.68%
on 12/24/25
+6.69 (+98.67%)
since 04/17/25

Most Recent Stories

More News
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

SAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

SGMT : 6.44 (-0.46%)
OMER : 13.47 (+0.22%)
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

– Permanent, product-specific J-code facilitates efficient claims and reimbursement –

OMER : 13.47 (+0.22%)
Omeros: Q4 Earnings Snapshot

Omeros: Q4 Earnings Snapshot

OMER : 13.47 (+0.22%)
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

– Conference Call Today at 4:30 p.m. ET

OMER : 13.47 (+0.22%)
Omeros Burns Cash While Everyone Waits for YARTEMLEA's Story

Barchart Research What to Expect from OMER Earnings OMER Generated March 30, 2026 Current Price $9.81 EPS Estimate $-0.55 Consensus Rating Moderate Buy Average Move 18.93% Omeros Burns Cash While Everyone...

OMER : 13.47 (+0.22%)
Omeros Has Been Quietly Burning Through Cash. This Week, the Story Either Changes or It Doesn't.

Barchart Research What to Expect from OMER Earnings OMER Generated March 27, 2026 Current Price $9.88 EPS Estimate $-0.55 Consensus Rating Moderate Buy Average Move 18.93% Omeros Has Been Quietly Burning...

OMER : 13.47 (+0.22%)
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026

Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the fourth quarter and year ended December 31, 2025, on Tuesday, March 31, 2026 after market close. Omeros...

OMER : 13.47 (+0.22%)
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52 nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on...

OMER : 13.47 (+0.22%)
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program

— OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients —

OMER : 13.47 (+0.22%)
Omeros Announces First Commercial Sales of YARTEMLEA®

— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA —

OMER : 13.47 (+0.22%)

Business Summary

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM)...

See More

Key Turning Points

3rd Resistance Point 14.83
2nd Resistance Point 14.38
1st Resistance Point 13.93
Last Price 13.47
1st Support Level 13.03
2nd Support Level 12.58
3rd Support Level 12.13

See More

52-Week High 17.65
Last Price 13.47
Fibonacci 61.8% 12.03
Fibonacci 50% 10.30
Fibonacci 38.2% 8.57
52-Week Low 2.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.